Abstract
Metastasis associated in colon cancer 1 (MACC1), a newly identified oncogene, has been associated with poor survival of cancer patients by multiple studies. However, the prognostic value of MACC1 in digestive system neoplasms needs systematic evidence to verify. Therefore, we aimed to provide further evidence on this topic by systematic review and meta-analysis. Literature search was conducted in multiple databases and eligible studies analyzing survival data and MACC1 expression were included for meta-analysis. Hazard ratio (HR) for clinical outcome was chosen as an effect measure of interest. According to our inclusion criteria, 18 studies with a total of 2,948 patients were identified. Pooled HRs indicated that high MACC1 expression significantly correlates with poorer OS in patients with digestive system neoplasms (HR = 1.94; 95% CI: 1.49–2.53) as well as poorer relapse-free survival (HR = 1.94, 95% CI: 1.33–2.82). The results of subgroup studies categorized by methodology, anatomic structure, and cancer subtype for pooled OS were all consistent with the overall pooled HR for OS as well. No publication bias was detected according to test of funnel plot asymmetry and Egger's test. In conclusion, high MACC1 expression may serve as a prognostic biomarker to guide individualized management in clinical practice for digestive system neoplasms.
Highlights
Digestive system neoplasms, including colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EC), pancreatic cancer (PC), and hepatocellular carcinoma (HCC), are among the top ten diseases for worldwide morbidity and mortality rate [1]
Metastasis associated in colon cancer 1 (MACC1) was newly identified as an oncogene regulating the hepatocyte growth factor/met tyrosine kinase receptor epidermal growth factor (HGF/c-Met) pathway which is well recognized to promote carcinogenesis and tumor progression by facilitating migration and invasion as well as suppressing apoptosis of cancer cells [3]
MACC1 expression has been further proven to contribute to unfavorable clinical outcome of patients with gastric cancer, esophageal cancer, and hepatocellular carcinoma [5, 9, 10]
Summary
Digestive system neoplasms, including colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EC), pancreatic cancer (PC), and hepatocellular carcinoma (HCC), are among the top ten diseases for worldwide morbidity and mortality rate [1]. Metastasis associated in colon cancer 1 (MACC1) was newly identified as an oncogene regulating the hepatocyte growth factor/met tyrosine kinase receptor epidermal growth factor (HGF/c-Met) pathway which is well recognized to promote carcinogenesis and tumor progression by facilitating migration and invasion as well as suppressing apoptosis of cancer cells [3]. MACC1 expression has been further proven to contribute to unfavorable clinical outcome of patients with gastric cancer, esophageal cancer, and hepatocellular carcinoma [5, 9, 10]. BioMed Research International a recent meta-analysis that included a total of 20 eligible studies with patients showed that overexpression of MACC1 was significantly associated with poorer survival in multiple solid tumors, including lung cancer, breast cancer, and glioma [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
